Researchers from Aligos Therapeutics Inc. and the Katholieke Universiteit Leuven reported on the preclinical activity of ALG-097558, a novel oral available 3CL protease inhibitor with pan-coronavirus antiviral activity.

Previous research demonstrated that the formation of PTEN-null tumors usually depends on the p100β catalytic isoform of PI3K (PI3Kβ); however, the mechanisms behind this dependency are unknown. In a recently published study, researchers from Dana-Farber Cancer Institute aimed to assess the role of PI3Kβ in immune evasion in PTEN-null breast cancer.

Researchers from Nanjing University of Traditional Chinese Medicine reported the discovery and preclinical characterization of fluorine-substituted selective estrogen receptor degraders (SERDs) as potential candidates for the treatment of estrogen receptor (ER)-positive breast cancer.

Despite advances in diagnosis and treatment, cardiovascular disease remains the leading cause of death worldwide. Single-nucleotide polymorphisms (SNPs) in microRNAs are known to play important roles in acute coronary syndrome (ACS). MicroRNA 146a (miR-146a) is significantly upregulated in human atherosclerotic plaques and its circulating levels are elevated in patients with ACS, and was thus the focus of a recent study.

Trueline Therapeutics Inc., a subsidiary of Anji Pharmaceuticals Inc., has successfully completed IND-enabling studies with Mcl-1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers. The company is now on track to initiate clinical development.

By analyzing gene expression patterns in the placenta of nearly 150 pregnancies and comparing them to fetal gene expression in the brain, researchers from the Lieber Institute for Brain Development have gained new insights into the importance of placental tissue in setting the risk trajectory for the development of schizophrenia. The work was published in Nature Communications on May 15, 2023.